【摘要】 目的观察国产多西他赛注射液对一线治疗后失败的晚期乳腺癌患者的临床疗效及毒副反应,并对安全性进行评估。方法以国产多西他赛对44例既往治疗后进展的乳腺癌患者进行70mg/m~2静脉滴注,每3周1次,单药治疗。试验中不预防使用粒细胞集落刺激因子。用世界卫生组织(WHO)的疗效及抗肿瘤药急性及亚急性毒性反应分度标准评价疗效及毒性,用卡式评分评价身体状况变化。结果在41例可评价疗效的患者中,4例达到完全缓解,14例部分缓解,有效率达43．9%,临床获益率85．4%。不良反应主要表现为Ⅲ、Ⅳ度白细胞下降(42．9%)、脱发(7．1%)和消化道反应(4．8%)。未出现水钠潴留。结论使用多西他赛注射液治疗化疗后进展的晚期乳腺癌患者,疗效显著,耐受性良好,可作为该类患者的治疗选择。更多还原

【Abstract】 Objective To evaluate the efficacy,toxicity and safety of an new domestic docetaxel in the treatment of pretreated advanced breast cancer.Methods Fourty-four breast cancer patients who had failed in first-line chemotherapy were included in this trial.They received docetaxel as the second-line chemotherapy.Docetaxel was administered alone at a dose of 70 mg/m~2 every 3 weeks.The use of granulocyte colony-stimulating factor to prevent granulocytopenia was not permitted.The response rate and toxicity were evaluated by World Health Organization toxicity scale and performance status by Karnofsky scale.Results Of the 41 evaluable patients,4 achieved complete response and 14 partial remission,with a response rate and clinical benefit rate of 43.9% and 85.4%,respectively.Grade 3 or grade 4 neutropenia developed in 42.9%,alopecia in 7.1% and vomiting in 4.8% of these patients.Fluid retention was not observed in this series.Conclusion Three-week administration of docetaxel alone at a dose of 70 mg/m~2 is effective and tolerable.It provides an alternative for the pretreated advanced breast cancer patients.更多还原